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ABSTRACT
Pancreatic cancer (PC) is one of the leading causes of cancer related deaths due 
to aggressive progression and metastatic spread. Aspartate β-hydroxylase (ASPH), 
a cell surface protein that catalyzes the hydroxylation of epidermal growth factor 
(EGF)-like repeats in Notch receptors and ligands, is highly overexpressed in PC. 
ASPH upregulation confers a malignant phenotype characterized by enhanced cell 
proliferation, migration, invasion and colony formation in vitro as well as PC tumor 
growth in vivo. The transforming properties of ASPH depend on enzymatic activity. 
ASPH links PC growth factor signaling cascades to Notch activation. A small molecule 
inhibitor of β-hydroxylase activity was developed and found to reduce PC growth by 
downregulating the Notch signaling pathway. These findings demonstrate the critical 
involvement of ASPH in PC growth and progression, provide new insight into the 
molecular mechanisms leading to tumor development and growth and have important 
therapeutic implications.
INTRODUCTION
Pancreatic cancer (PC) is the 4th leading cause of 
cancer-related death in USA, with an estimated 45,220 
new cases and 38,460 deaths in 2013 [1, 2]. Despite 
improvements in detection and management, the 5-year 
survival rate of PC is only 5-6%. At diagnosis, 80-85% 
of patients present with advanced unresectable disease 
due to invasion and widespread metastasis. Pancreatic 
cancer is notoriously aggressive and refractory to 
treatment [1, 2]. There is a need to explore the molecular 
mechanisms of PC development, progression and 
metastasis in an attempt to identify new molecular 
targets for therapy. Aspartate β-hydroxylase (ASPH) is 
an ∼86KD Type II transmembrane protein and a member 
of the α-ketoglutarate-dependent dioxygenase family [3, 
4]. ASPH catalyzes the β-hydroxylation of aspartyl and 
asparaginyl residues in epidermal growth factor (EGF)-
like repeats of various proteins such as Notch, Jagged 
(JAG) and Delta-like (DLL) [5]. Notch signaling plays 
critical roles in cell growth, differentiation, adhesion, 
migration and metastasis [6]. 
This study examines the expression of ASPH in 
human PC cell lines and pancreatic ductal adenocarcinoma 
(PDAC) tumor tissues, as well as determines how ASPH 
activates Notch signaling as a major contributor to 
generation of malignant phenotypes. We demonstrated 
that ASPH exerts effector function by promoting 
cell proliferation, migration, invasion, and malignant 
transformation. More important, PC tumor growth and 
progression may be altered by a small molecule inhibitor 
(SMI) of ASPH β-hydroxylase activity. 
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RESULTS
Overexpression of ASPH generates a malignant 
phenotype
The level of ASPH expression was determined by 
immunohistochemical staining (IHS) in human pancreatic 
ductular adenocarcinomas (PDACs) (n=104), pancreatic 
neuroendocrine tumors (n=7), as well as acute or chronic 
pancreatitis (n=12), compared to adjacent normal pancreas 
(n=12), and normal intestine (n=12) as shown in Fig. 1. 
There was substantial ASPH protein expression in 101 
of 104 PDACs (97.1%) on tissue microarrays (TMAs), 
and no immunoreactivity was observed in pancreatitis, 
normal pancreas, intestine or pancreatic neuroendocrine 
tumors (Fig. 1a, b). Most PDACs had a strong staining 
Fig. 1: ASPH expression in human PDAC, pancreatic neuroendocrine tumor, acute and chronic pancreatitis, normal pancreas and 
normal intestine. (a1) Typical ASPH expression in PDAC at 40× in tissue microarrays (TMAs) from 104 tumors. (a2) A representative 
example of IHS with mAb FB-50 (400×). (a3) A representative PDAC at 40× stained with a negative control mAb against hepatitis B 
surface antigen of the same isotype as mAb FB-50. (a4) Normal adjacent pancreas stained with the anti-ASPH FB-50 mAb (400×). (b) 
A summary of positive and negative expression of ASPH by IHS in normal tissues, pancreatitis and pancreatic tumors. (c) A bar graph 
of staining intensity with a mean score of 2.31 for PDACs where 0 = no, 1 = weak, 2 = moderate, 3 = strong expression of ASPH by 
IHS. Fig. 1. (d) Activated Notch1 and HES1 were also overexpressed in the cytoplasm and nuclei of tumor tissue compared to adjacent 
normal pancreas of PC patients (400×). The arrows highlight the positive staining of activated Notch1 and HES1 in the nuclei of tumor 
cells in representative examples. (e) Expression profiling of ASPH and Notch signaling proteins in 7 human PC cell lines. Most PC cell 
lines showed upregulation and activation of C-terminal intracellular Notch (ICN) 1, 2, 4 and to a lesser extent, Notch 3 as determined by 
Western blot analysis. The Notch ligands Jagged (JAG) 1 and 2 were expressed in 4/7 and 5/7 of the cell lines, respectively. In contrast, 
Delta (DLL) 1 and 4 were infrequently upregulated. (f) Lentiviral transfection and stable expression of ASPH in MIA PaCa2 cells. Note 
the cell surface localization of ASPH after stable overexpression by lentivirus as depicted in the middle panel as compared to the empty 
vector stable transfected control. 
Oncotarget1233www.impactjournals.com/oncotarget
intensity (Fig. 1c). Activated Notch1 and HES1 were also 
overexpressed in the cytoplasm and nuclei of PDAC tumor 
cells (Fig. 1d).
The expression profiling of ASPH in 7 human 
PC cell lines was examined by Western blot analysis. 
High levels of the 86kD ASPH proteins were found in 
HPAFII, AsPC-1, Hs766T and Panc-1; very low levels 
were observed in BxPC-3 and MIA PaCa2 and little, if 
any, expression was noted in Capan-1 cells. Expression 
profiling of Notch signaling proteins is presented for 
comparison in Fig. 1e. We prepared lentiviral mediated 
stable transfection of ASPH that localized to the cell 
surface in MIA PaCa2 cells (Fig. 1f) with very low 
endogenous levels of ASPH as described [7, 8]. Empty 
vector transfected cells served as the control. 
Figure 2 panel a-e demonstrate the biological effects 
of ASPH overexpression on the PC cell phenotype on MIA 
PaCa2 as measured by proliferation, migration, invasion, 
as well as colony formation as an index of malignant 
transformation. Similar findings were evident with 
stable ASPH transfected Capan-1 cells (data not shown). 
This aggressive malignant phenotype was significantly 
attenuated by specific shRNAs “knockdown” of ASPH in 
AsPC-1 cells with high endogenous levels as demonstrated 
by a reduction in proliferation, migration, invasion and 
colony formation (Fig. 3, panel a-e). 
β-hydroxylase activity is necessary for ASPH to 
function as a transforming protein
The C-terminus of ASPH contains the amino acid 
(aa) sequence of the catalytic site, (M670HPGTH675) and its 
sequence is identical in human, rat, mouse and cattle [9]. 
The H675 aa is specifically involved in Fe2+ coordination 
and is critical for its enzymatic activity; H675 aa is also 
highly conserved in the chicken and fly [10]. 
We have established WT-ASPH and H675Q mutant 
expression constructs (Fig. 4a, b, c). The human H675Q 
mutant ASPH has an 80% reduction in enzymatic activity 
and was subsequently examined to determine if there 
would be a loss in ability to promote cell proliferation, 
migration, invasion, and colony formation compared 
to the “wild type” protein. Figure 5 illustrates the 
stimulatory effects of WT-ASPH overexpression in PC 
cells on proliferation, migration, invasion, and colony 
formation, as well as the activation of Notch responsive 
genes. However, the mutant ASPH H675Q inhibited cell 
proliferation, migration, invasion, and colony formation 
as well as reduced HES1, HEY1, CD44, EpCAM, c-Myc, 
MMP2/9, cyclin D3, and PCNA gene expression in PC 
cells. 
ASPH generates a malignant phenotype in PC 
through Notch activation
Notably, ASPH overexpression activated Notch 
responsive genes such as HES1, HEY1, CD44, EpCAM, 
c-Myc, MMP2/9, cyclin D3, and PCNA (Fig. 2f). To 
further link ASPH expression to Notch activated genes, 
we performed shRNA “knockdown” experiments in 
AsPC-1 cells as demonstrated in Fig. 3f. Lentiviral 
induced stable cell lines expressing scrambled shRNA 
showed the expected high level of endogenous expression 
of ASPH and prominent upregulation of HES1, HEY1, 
CD44, EpCAM, c-Myc, MMP2/9, cyclin D3, and 
PCNA. In contrast, AsPC-1 cells stably transfected with 
3 different specific ASPH targeted shRNAs demonstrated 
downregulation of these Notch responsive genes.
We determined if Notch1 and JAG2 directly interact 
with and bind to ASPH by co-immunoprecipitation 
experiments. As displayed in Fig. 4d, e, Notch1 and JAG2 
directly interact with ASPH. Interestingly, this physical 
interaction property was maintained with the mutant 
H675Q ASPH construct, suggesting that the protein-protein 
binding sites between ASPH and Notch1/JAG2 may be 
independent from the enzymatic activity since a H675Q 
mutation in the catalytic site has been previously shown 
to reduce β-hydroxylase to 20% of “wild type” (WT) 
levels [11]. ASPH expression also promoted nuclear 
translocation of the C-terminal ICN of Notch1 into the 
nucleus of MIA PaCa2 cells overexpressing WT-ASPH 
(Fig. 4f). In contrast, nuclear accumulation of activated 
Notch1 ICN was inhibited with loss of enzymatic activity 
caused by H675Q mutation in ASPH as displayed in Fig. 4f.
High throughput screening assay for ASPH 
β-hydroxylase activity inhibitors.
An assay to measure ASPH β-hydroxylase activity 
had been established as described [11, 12]. This high 
throughput system was used to screen for potential small 
molecule inhibitors (SMIs) of β-hydroxylase activity that 
were synthesized as shown in Fig. 6a. When inhibitors of 
ASPH β-hydroxylase activity were identified, a functional 
MTT assay over a range of drug concentrations was 
performed to assess their effects on cell viability and 
growth. Examples of positive and negative results among 
several candidate compounds are depicted in Fig. 6b. 
These SMIs were rationally designed based upon the 
aminohydroxyfuranone ring core. There was a “strong hit” 
with one of the MO-I-1100 compounds since it reduced 
β-hydroxylase activity by 80% and cell viability over a 
range of concentrations (Fig. 6b). 
The biological effects of reduced ASPH enzymatic 
activity on generation of a malignant phenotype was 
evaluated. Figure 7 demonstrates the inhibitory effects 
of MO-I-1100 on ASPH induced proliferation, migration, 
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Fig. 2: Stable overexpression of ASPH in MIA PaCa2 cells promotes cell proliferation. (a), wound healing (b), migration (c), invasion 
(d), and colony formation (e) as indices of changes in the malignant phenotype. ASPH overexpression also enhances the expression of 
activated Notch1, JAG2, and Notch signaling downstream target genes including HES1, HEY1, EpCAM, CD44, c-Myc, MMP2/9, cyclin 
D3 and PCNA as shown in Western blot analysis (f). *p<0.05; **p<0.01; ***p<0.001.
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Fig. 3: Knockdown of ASPH by specific shRNAs in AsPC-1 cells inhibited (a) proliferation, (b) wound healing, (c) migration, (d) 
invasion, and (e) colony formation as indices of changes in the malignant phenotype. (f) Endogenous overexpression of ASPH was 
associated with upregulation of activated Notch1 and JAG2, as well as Notch signaling downstream target genes HES1, HEY1, EpCAM, 
CD44, c-Myc, MMP2/9, cyclin D3 and PCNA in a lentiviral transfected stable cell line expressing a nonspecific scrambled shRNA. The 
AsPC-1 cell lines stable transfected with ASPH specific shRNAs demonstrated downregulation of activated Notch1, JAG2, and Notch 
activated genes as determined by Western blot analysis. *p<0.05; **p<0.01; ***p<0.001. 
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Fig. 4: ASPH gene was subcloned into pcDNA3 with 5’ c-Myc tagged vector. Inclusion of a c-Myc-tag allowed discrimination 
of exogenous expressed protein from endogenous cellular levels. (a) “Wild type” (WT) ASPH construct; (b) ASPH mutant (H675Q) 
construct where enzymatic activity was reduced to 20% of “wild type” protein level; (c) Western blot analysis of WT and mutant proteins 
with antibodies to ASPH and c-Myc. A direct physical interaction of ASPH with (d) Notch1 or (e) JAG2 by co-immunoprecipitation (IP) 
was observed in MIA PaCa2 cells. ASPH, Notch1, and JAG2 immunoprecipitates were fractionated by SDS-PAGE and analyzed by 
Western blot using the FB-50 monoclonal antibody. The negative control (Neg) corresponds to an IP result using non-relevant antibody to 
hepatitis B virus. (f) Microscopy showing increased nuclear translocation of activated Notch1 ICN in the nuclei of MIA PaCa2 cells stably 
expressing WT-ASPH. Note that the mutant H675Q ASPH substantially reduces nuclear localization of Notch1 ICN comparable to that in 
vector transfected MIA PaCa2 cells, which suggests that the enzymatic activity of the protein is critical for Notch activation.
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Fig. 5: The β-hydroxylase activity of ASPH is required for its transforming activity. MIA PaCa2 cells were stably transfected with 
empty vector (EV), “wild type” (WT)-ASPH, or H675Q-ASPH mutant and the levels of expression were confirmed by Western blot. There 
is low-level endogenous ASPH in MIA PaCa2 cells as shown here and in Fig. 1. Effects of EV, WT-ASPH and H675Q-ASPH on (a) 
cell proliferation, (b) migration, (c) invasion, and (d) colony formation are significantly different. (e and f) represents a Western blot 
demonstrating WT-ASPH induced activation of Notch signaling as determined by increased levels of Notch1 ICN, JAG2, as well as 
increased expression of downstream responsive genes HES1, HEY1, EpCAM, CD44, c-Myc, MMP2/9, cyclin D3 and PCNA. In contrast, 
the mutant H675Q ASPH construct shows significantly reduced activated Notch1 ICN, JAG2, as well as HES1, HEY1, EpCAM, CD44, 
c-Myc, MMP2/9, cyclin D3 and PCNA. The results suggest that the β-hydroxylase activity of ASPH is essential for Notch signaling 
activation. *p<0.05; **p<0.01; ***p<0.001.
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Fig. 6: (a) Candidate parent compounds selected and evaluated as potential inhibitors of ASPH β-hydroxylase activity were synthesized on 
the basis of the crystal structure of the catalytic site in the C-terminal region of ASPH using computer assisted drug design. (b) Effects of 
SMIs on cell viability of FOCUS HCC cells that highly expressed ASPH on the cell surface as a drug screen for biological activity. Note 
that MO-I-1100 demonstrated a dose dependent effect on cell viability over a range of 0.03 – 3 µM whereas other compounds such as MO-
I-100, 300 and 400 for example, showed little, if any, activity.
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Fig. 7: Effect of SMI MO-I-1100 on the PC phenotype induced by exogenous or endogenous high-level of WT-ASPH expression. 
MIA PaCa2 cells stably transfected with empty vector or the “wild type” ASPH construct via lentiviral transfection depicted in Fig. 2. 
The inhibitory effects of MO-I-1100 on (a) proliferation, (b) migration, (c) invasion, and (d) colony formation of MIA PaCa2 cells were 
observed. There is a significant reduction in the expression of Notch1 ICN, JAG2, as well as downstream responsive genes HES1, HEY1, 
EpCAM, CD44, c-Myc, MMP2/9, cyclin D3 and PCNA induced by MO-I-1100 compared to the DMSO treatment (e and f). *p<0.05; 
**p<0.01; ***p<0.001.
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invasion and colony formation, as well as Notch signaling 
activation in MIA PaCa2 cells with high expression of 
WT-ASPH. 
To further link the association between ASPH 
overexpression and Notch activation, we treated MIA 
PaCa2 cells with a γ-secretase inhibitor (DAPT) as 
shown in Fig. 8. Treatment reduced PC proliferation, 
migration and colony formation. Similar results were 
obtained with HPAFII and AsPC-1 PC cells which have 
high endogenous levels of ASPH indicating that enhanced 
migration and invasion could be inhibited by MO-I-1100, 
a SMI of ASPH β-hydroxylase activity in vitro under these 
conditions as well (Fig. 8d-g). 
Inhibition of ASPH β-hydroxylase activity 
reduces PC tumor development and growth in 
immunodeficient mice 
Studies were performed to determine if ASPH 
overexpression can promote tumor growth in Balb/c nude 
mice inoculated subcutaneously (s.c.) with MIA PaCa2 
cells. Tumor growth rates are demonstrated in Fig. 9a, 
where ASPH overexpression accelerated tumor formation 
compared to tumors induced by stable vector transfected 
controls. 
It was of interest that MO-I-1100 had no effect 
on tumor development and growth induced by stably 
Fig. 8: The γ-secretase inhibitor DAPT (at a concentration of 10 µM) reversed the aggressive malignant phenotype exhibited by 
ASPH overexpression in MIA PaCa2 cells. DAPT attenuated ASPH induced (a) cell proliferation, (b) migration and (c) colony formation 
through inhibition of Notch1 ICN signaling. A SMI (MO-I-1100) exerted inhibitory effects on the PC phenotype induced by endogenous 
high-level of ASPH expression. A significant reduction in (d, e) migration and (f, g) invasion was observed in HPAFII and AsPC-1 PC cells 
with high endogenous levels of ASPH (Fig. 1) treated with MO-I-1100 at 5 µM. *p<0.05; **p<0.01; ***p<0.001 when compared with 
control. 
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Fig. 9: Effect of a SMI (MO-I-1100) on PC tumor growth in subcutaneous (s.c.) tumor model of nude mice. (a) ASPH transfected 
MIA PaCa2 cells had high tumorigenicity compared to MIA PaCa2 cells transfected with empty vector. Growth curve on 8 animals in 
each group indicated enhanced tumor development induced by ASPH overexpression. (b) represents tumor growth curves derived from 
MIA PaCa2 cells stably transfected with empty vector or a WT-ASPH expression construct as delivered by lentivirus. Note that anti-tumor 
effects exhibited by MO-I-1100 were observed only in tumors with exogenous ASPH overexpression. Each group had 10 animals. Effect 
of MO-I-1100 on Notch signaling in vivo has been observed. Tumors taken from the growth curve that were responsive to MO-I-1100 
treatment depicted in (b) were analyzed for Notch signaling compared to untreated control. There were 3 tumors taken from the MO-I-1100 
treatment group and 3 from the untreated control. (c) demonstrates that the expression of the Notch1 ICN is substantially downregulated 
by the SMI of APSH β-hydroxylase activity by IHS. (d) represents reduction in the expression of JAG2, as well as Notch activated genes 
HES1 and PCNA following MO-I-1100 treatment. Similar inhibitory effects of MO-I-1100 on PC tumor growth in vivo were observed in 
(e) HPAFII and (f) AsPC-1 cells induced s.c. tumors. These human PC cell lines had high endogenous expression of ASPH as shown in 
Fig. 1a. *p < 0.05; **p< 0.01. 
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transfected empty vector control MIA PaCa2 (Fig. 9b). 
Since the only difference between these two cell lines was 
the presence or absence of exogenous ASPH expression, 
PC tumor development and growth may be most 
susceptible to a SMI of β-hydroxylase activity in those 
tumors that have high levels of ASPH expression. 
Furthermore, established large tumors generated by 
MIA PaCa2 cells stably overexpressing ASPH and vector 
control were available for analysis of Notch signaling 
after MO-I-1100 treatment as shown in Fig. 9c, d. Tumor 
growth that was inhibited by MO-I-1100 treatment was 
analyzed for Notch1 ICN expression, which demonstrated 
a reduction in cytoplasmic and nuclear accumulation 
following treatment as shown in Fig. 9c. In addition, there 
was a downregulation of Notch responsive genes in these 
tumors as demonstrated by reduced JAG2, HES1 and 
PCNA expression as illustrated in Fig. 9d. The antitumor 
effects of blocking ASPH β-hydroxylase activity was 
also assessed in immunodeficient mice with two other PC 
cell lines that have high endogenous ASPH expression 
(HPAFII and AsPC-1). The results suggest that reducing 
the β-hydroxylase activity with MO-I-1100 treatment has 
substantial effects on PC tumor growth as shown in Fig. 
9e, f.
DISCUSSION
The Notch signaling cascade is a highly 
conserved pathway that principally controls cell fate 
determination during embryogenesis by facilitating 
cell-cell communications. It is a major regulator of 
cell proliferation, migration, and invasion, and plays 
a prominent role in apoptosis [13]. The transcriptional 
program mediated by this signaling cascade includes 
upregulation of the well characterized HES and HEY 
family of transcription factors. Some of the other well-
known and characterized downstream target genes include 
P21, c-Myc, PDGFR, EGFR, WNT 3/4, PTEN, Bcl-2, 
cyclin D 1/3, cyclin E1, MMP2/9, CD44, EpCAM and 
PCNA [14-18]. Several investigations suggest that the 
expression and activation of Notch receptors and ligands 
appear to be downregulated in the normal adult pancreas 
[13], only to re-emerge during pancreatic oncogenesis. 
ASPH has negligible to very low expression in 
normal adult human tissue with the notable exception of 
the placenta, an invasive tissue, where its expression is 
robust [19, 20]. ASPH is expressed in many organs during 
embryogenesis, presumably to promote cell migration 
for organ development. Its expression is “shut off” in the 
adult only to re-emerge during oncogenesis where it may 
be required for generation of malignant phenotypes [11, 
12, 21]. Transcriptional regulation of ASPH is provided 
by tripartite signaling pathways: insulin (IN) and insulin 
like growth factor 1 (IGF1)/insulin-receptor substrate 
type 1 (IRS1)/MAPK/ERK, IN/IGF1/IRS1/PI3K/
AKT, and WNT/β-Catenin [22, 23]. Post-transcriptional 
regulation of ASPH is mediated by phosphorylation of 
GSK3β-related motifs located in the N-terminal region 
of the molecule [24]. The present study attempts to 
address several questions central to the function of ASPH 
in PC. Is ASPH a major activator of Notch signaling in 
PC to promote cell proliferation, migration, invasion 
and malignant transformation? Is the enzymatic activity 
central to its biological function as a transforming protein? 
Can the β-hydroxylase activity be inhibited by SMIs to 
produce antitumor effects in preclinical animal models 
which could be extended to patients in the future? Is the 
biological activity of ASPH dependent on Notch signaling 
as a central mechanism for generating its oncogenic 
properties?.
Activation of Notch signaling may be one of the 
major factors involved in PC development and growth. 
There is ample evidence to suggest that the upregulation 
of Notch receptors and ligands [25] is a common feature 
of such tumors [26] which leads to enhanced expression 
of downstream Notch target genes [13, 27, 28]. Notch 
signaling, which is induced by overexpression of 
its receptors and ligands, may be required for tumor 
maintenance [29]. However, characterization of other 
activators of the Notch cascade in PC and how they may 
be connected is not well established [13]. 
ASPH is significantly upregulated in PC patients 
as shown in Fig. 1. These observations suggest that 
ASPH may play an important role in PC pathogenesis. 
We observe that ASPH expression was negative by IHC 
in grade 1 and 2 PanINs. There is very weak staining 
for ASPH expression with grade 3 PanINs with more 
advanced cytological atypia characterized by mitotic 
figures, pleomorphism and hyperchromatic nuclear 
staining and prominent nucleoli. Thus, ASPH appears 
to be overexpressed primarily in the fully transformed 
malignant phenotype with little, if any, expression 
in premalignant lesions. These findings suggest that 
the protein may play an important role in the PC 
transformation process. Of interest is that metastatic 
spread of PC to regional lymph nodes was highly positive 
for ASPH expression (7 lymph nodes were examined 
derived from 4 different tumors). As shown in Fig.1d, 
ASPH staining is correlated with enhanced activated 
Notch 1 and HES1 expression. It has been reported that 
ASPH high expression is associated with poor survival of 
HCC and cholangiocarcinoma patients [21, 30]. We are 
currently obtaining similar information on PC patients to 
determine the relationship between ASPH expression in 
tumor tissue and clinical outcome. ASPH protein may be 
also involved in other biological processes, besides the 
Notch pathway, to promote PC development and there is 
evidence that expression inhibits apoptosis, stimulates cell 
proliferation and prevents development of senesecence by 
other non-Notch related cascades (unpublished). 
The purpose of measuring the expression profiling 
of ASPH and Notch (full-length [FL] and intracellular 
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domain [ICN]) pathway components is to identify these 
PC cell lines with low vs. high endogenous ASPH 
expression and to subsequently make the stable cell lines 
with exogenous overexpression of ASPH vs. knockdown 
of ASPH in the presence of Notch receptors and ligands 
(for example, JAGs) for further investigations on the 
molecular mechanisms of PC carcinogenesis. Lentiviral 
induced ASPH overexpression in MIA PaCa2 PC cells 
with low endogenous expression levels was notable for 
translocation of the protein to the tumor cell surface. This 
ultimately conferred a malignant phenotype, characterized 
by enhanced proliferation, migration, invasion and 
colony formation. The β-hydroxylase activity of ASPH 
appeared central to its function, as the expression of the 
H675Q mutant construct, which had an 80% reduction of 
enzymatic activity reversed this cellular phenotype (Fig. 
5). 
The development and characterization of SMIs 
of β-hydroxylase activity was informative. Based 
on this high-throughput screening approach and the 
crystal structure of the ASPH catalytic site, a number of 
potential candidate SMIs were synthesized. We found 
that a MO-I-1100 compound was a potent inhibitor of 
ASPH and reduced enzymatic activity by about 80% 
compared to the “wild type” protein. In this regard, MO-
I-1100 substantially inhibited PC cell migration and 
invasion in HPAFII and AsPC-1 cell lines, which have 
high endogenous levels of ASPH. In addition, similar 
effects were observed in MIA PaCa2 cells with stable 
overexpression of exogenous ASPH. More importantly, 
MO-I-1100 treatment of nude mice bearing s.c. grown 
tumors induced by these three PC cell lines reduced tumor 
growth and progression. It was of interest that MO-I-1100 
was effective on PC tumors that expressed ASPH, but 
appeared inactive in parenteral PC cells with low ASPH 
levels. These findings raise the possibility that a high level 
of ASPH expression in human PC tumors may be a useful 
biomarker for selection of tumors that could respond to 
SMIs of β-hydroxylase as a potential therapeutic approach. 
Little is known regarding the factors and signaling 
pathways that activate the Notch cascade in PC. The 
observation that IN/IGF1/IRS1/RAS/RAF/MAPK/ERK, 
IN/IGF1/IRS1/PI3K/AKT and WNT/β-catenin pathways 
upregulate ASPH at the transcriptional level and crosstalk 
with each other [31-33] links these growth factor signaling 
cascades that are commonly upregulated in PC [34-45] 
to Notch activation through ASPH. Overexpression of 
ASPH activates Notch by promoting cleavage of Notch1 
ICN to liberate the C-terminal ICN and subsequently 
upregulates, at the transcriptional level, a number of 
downstream Notch responsive genes such as HES1, 
HEY1, CD44, EpCAM, c-Myc, MMP2/9, cyclin D3, and 
Fig. 10: Hypothesis of how ASPH may be involved in the pathogenesis of PC progression through Notch activation [6]. The structure 
of ASPH molecule consists of cytoplasmic (green), transmembrane (purple), luminal region (blue) and catalytic domain (red), which 
contains the catalytic site (M670HPGTH675). (a) In the presence of β-hydroxylase activity of ASPH, binding of the JAG ligand (green) on 
one cell to the Notch receptor (purple) on another cell results in two proteolytic cleavages of the receptor. The ADAM10 or TACE (TNF-
α-converting enzyme; ADAM17) metalloprotease (black) catalyzes the S2 cleavage and generates a substrate for S3 cleavage by the 
γ-secretase complex (red). This proteolytic processing mediates release of the Notch intracellular domain (NICD), which enters the nucleus 
and interacts with the DNA-binding CSL (CBF1, Su(H) and LAG-1) protein. The co-activator Mastermind (Mam) and other transcription 
factors are recruited to the CSL complex, whereas co-repressors (Co-R) are released. Thus, the Notch signaling is on and the downstream 
target genes are expressed: CD44 and EpCAM are markers for cancer stem cells; PCNA, cyclin D3, c-Myc, MMP2/9, HES1 and HEY1 
are involved in cell proliferation, migration, invasion, tumor growth and metastasis in PC. (b) SMIs block the catalytic site of ASPH, which 
leads to loss of β-hydroxylase activity and failure of JAG2 binding to Notch1. Thus, Notch signaling is off and its oncogenic effector is 
inhibited in PC.
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PCNA. Moreover, a mutation (H675Q) in the catalytic site, 
as well as a SMI of ASPH β-hydroxylase activity, reverses 
ASPH mediated Notch activation. In addition, treatment of 
ASPH overexpressing PC cells with a γ-secretase inhibitor 
(DAPT) reduced a phenotype of enhanced migration, 
invasion and colony formation which suggests that ASPH 
effector activity may be mediated through Notch signaling. 
Figure 10 depicts a working hypothesis of how 
ASPH contributes to PC development and progression. 
In this scheme, overexpression of ASPH is followed by 
translocation to the cell surface where it directly interacts 
with Notch (Fig. 4). Notch receptors contain 36 EGF-like 
repeats in the extracellular domain (NECD), which are the 
substrates of ASPH β-hydroxylase. ASPH may facilitate 
the interactions of the Notch receptors with their ligands 
(such as JAG and DLL). It is hypothesized that enhanced 
Notch receptor-ligand interaction leads to the generation 
of activated Notch1 ICN followed by upregulation of 
downstream responsive target genes. The net biological 
effect is to promote cell proliferation, migration, 
invasion, tumor growth and metastasis, which leads to PC 
development and progression; this cellular phenotype is 
attenuated by a SMI of ASPH β-hydroxylase activity. 
MATERIALS AND METHODS 
Cell Culture 
The human PC cell lines AsPC-1, BxPC-3, Capan-1, 
HPAF-II, Hs766T, MIA PaCa2 and Panc-1, as well as 
hepatocellular carcinoma cell line HepG2 (positive 
control) were purchased from American Type Culture 
Collection. All cell lines have been authenticated by 
short tandem repeat profiling to reduce the frequency 
of cell misidentification. Cells were cultured at 37°C 
in a humidified atmosphere containing 5% CO2 in 
corresponding media supplemented with 10% FBS and 
antibiotics (penicillin and streptomycin). Cells were 
passaged when they reached 80% confluence.
Lentiviral infected stable cell line with 
overexpression or knockdown of ASPH
We established two stable MIA PaCa2 cell lines 
with overexpression of ASPH, and three stable AsPC-1 
cell lines with knockdown of ASPH by specific shRNAs 
using the lentiviral system (GeneCopoeia, #EX-Z8758-
Lv105 and # HSH011500-HIVU6, respectively) as 
described [7, 8]. Three shRNAs sequences used to 
target ASPH were as follows: [HSH011500-1-HIVU6 
(OS217501)] cttctccatgaaatggtac, [HSH011500-2-HIVU6 
(OS217502)] ctggaacctgaagtatctc, and ([HSH011500-3-
HIVU6 (OS217503)] cctgaggataatcctgtag. 
Western Blot Analysis 
Cell lysates were separated by SDS PAGE and 
transferred to nitrocellulose membranes. Western blot 
analysis was performed by using primary antibodies 
against ASPH; JAG1, JAG2, DLL1, DLL4, Notch1, 
Notch2, Notch3, Notch4, c-Myc, matrix metalloproteinase 
(MMP)-2, epithelial cell adhesion molecule (EpCAM), 
and CD44 (Cell Signaling Technology #2620, #2205, 
#2588, #2589, #4380, #4530, #5276, #2423, #5605, 
#13132, #2929, #5640, respectively); activated Notch1, 
HES1 and HEY1 (Abcam ab8925, ab71559, ab22614, 
respectively); cyclin D3, MMP9, and proliferating cell 
nuclear antigen (PCNA) (Santa Cruz, sc-56307, sc-21733, 
sc-7907, respectively). Protein bands were visualized 
by IRDye® 680RD Infrared Dye and IRDye® 800CW 
Infrared Dye and exposed on Odyssey image system (LI-
COR).
MTT 
Cell proliferation was analyzed using the MTT 
assay. Sable PC cells (MIA PaCa2 and AsPC-1) 
transfected with vector, ASPH or ASPH-shRNA (1.5 × 104 
cells per well) were seeded in 24 well plates and cultured 
for 4 days. Fresh media were changed every 2 days. Cells 
were incubated with MTT solution (Sigma-Aldrich) in 
corresponding media (10% v/v) at 37°C for 3 h. Then 
0.1 N HCI isopropanol was added. Plates were analyzed 
daily at a wavelength of 570 and 690 nm, respectively. The 
background absorbance of multiwall plates measured at 
690 nm was subtracted from the measurement at 570 nm.
Wound healing assay 
Stable PC cells (MIA PaCa2 and AsPC-1) 
transfected with ASPH or vector were seeded in a 6-well 
plate and cultured to reach 80% confluence. Cells were 
starved for 24 h in corresponding media containing 1% 
FCS before a scratch was made using a 200 µl pipette 
tip. The wounded monolayer was washed with PBS, 
incubated with 5% FCS, and photographed using a 
microscope. Cells were incubated for an additional 24 h 
and then photographs were taken of the wounded area. 
All data were obtained from at least three independent 
experiments.
Migration, Invasion and Colony Formation 
Assays
Assays to measure PC cell migration, invasion and 
colony formation were performed as described previously 
[7, 8].
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Generation of a small molecule inhibitor (SMI) of 
ASPH enzymatic activity
Synthesis and characterization of novel SMI for ASPH 
Based on the crystal structure of the ASPH catalytic 
site, computer generated drug design was performed, 
leading to the synthesis of a series of parent compounds 
and derivatives likely to fit into the pocket of the catalytic 
site and inhibit the β-hydroxylase activity. Figure 6 
listed some of the parent compounds synthesized and 
examined for inhibition of β-hydroxylase activity using 
a high throughput screening assay. Synthesis of SMIs 
was accomplished in two steps. The first step was a three-
component reaction including an aromatic aldehyde, 
glyoxal bisulfate addition product, and potassium 
cyanide to yield an arylhydroxytetronimide. In the second 
step arylhydroxytetronimide was sulfonylated with 
phenylmethansulfonyl chloride in dry tetrahydrofuran 
to yield. Compounds were characterized by 1H and 
13C nuclear magnetic resonance, high resolution mass 
spectroscopy, high performance liquid chromatography, 
infra-red spectroscopy, melting point, elemental analysis 
and binding to ASPH by isothermal titration calorimetry. 
Subcutaneous tumor model 
This research was approved by the Institutional 
Animal Care and Use Committee of Rhode Island 
Hospital. Athymic BALB/c male nude mice (Charles River 
laboratory) were housed in laminar flow cabinets under 
specific pathogen-free conditions and studied at 5-6 weeks 
of age. Stable MIA PaCa2 cells, in exponential phase of 
growth were transfected with vector or ASPH lentiviral 
expression. In addition, AsPC-1 and HPAFII cells were 
harvested, washed, and resuspended in Ca2+/Mg2-free 
HBSS, and adjusted to the desired cell concentration. 
Cell viability was determined by trypan blue exclusion 
and single-cell suspensions containing >90% viable cells 
was employed. In the subcutaneous (s.c.) model, tumor 
cells (5×105 to 5×106 in 0.2 mL of HBSS) were injected 
s.c. into the left (vector) and right (ASPH) shoulder 
of the nude mice, respectively. Growth of tumors was 
monitored by measuring the tumor size with calipers 
every 3 days. The tumor volume (mm3) was calculated 
using the formula: length × depth × depth × 0.5236. The 
mice were sacrificed after 2 weeks. The tumors were 
harvested, weighed and fixed with 10% neutral buffered 
formalin. Immunohistochemical staining for nuclear 
accumulation of Notch1 intracellular domain (ICN) and 
Western blot analysis of Notch signaling molecules were 
also performed.
Drug treatment of animal models
The xenograft model employed s.c. injected PC 
cell lines with high levels of exogenous or endogenous 
ASPH expression. They were injected s.c. into the right 
shoulder at a concentration of 5×105 varying to 5×106 
cells depending in part on the cell lines employed. 
These cell concentrations would produce tumors in 
approximately 100% of control male nude mice. The left 
shoulder was implanted with vector-transfected PC cell 
lines for comparison with the right shoulder implanted 
with a high ASPH expressing cell line such as AsPC-
1. Tumor growth rate was monitored every 3 days. The 
animals were sacrificed when tumors reached 2.5 cm (per 
request of the Animal Studies Committee). Tumors were 
dissected, weighed, frozen and stored to measure Notch 
signaling expression by immunohistochemistry (IHC) 
and Western blot analysis. PC cell lines were allowed 
to form established tumors before initiation of treatment 
with SMIs so that measurements of the above parameters 
could be made before and after therapy with MO-I-1100 
(a comparison between initially untreated tumors and 
treated residual PC). Eight to 10 animals were employed 
in each group (treatment and control). The dose range 
of MO-I-1100 was 20, 40, and 60 mg/kg administered 
intraperitoneally (i.p.). 
Immunohistochemistry 
Tissue microarrays (TMAs) containing pathologic 
specimens from 104 individuals with state I/II PDAC 
were used for IHC. Those patients had undergone 
pancreaticoduodenectomy at Lifespan Rhode Island 
and the Miriam Hospitals, Warren Alpert School of 
Medicine, Brown University. The study was approved 
by the Institutional Review Board of Lifespan Rhode 
Island and the Miriam Hospitals. Immunohistochemical 
staining was conducted on 4-um formalin-fixed paraffin-
embedded (FFPE) unstained sections using the FB-50 
mAb. The sections were deparaffinized in xylene and 
rehydrated in a descending ethanol gradient. Antigen 
retrieval was performed using Citric Acid Based Antigen 
Unmasking Solution (Vector Laboratories, Burlingame, 
CA) in a microwave pressure cooker (Nordic Ware, 
Minneapolis, IN) for 6 min at full power, followed by 
a 30 min cool down process. Endogenous peroxidase 
activity was quenched by a 30 min treatment with 3% 
hydrogen peroxide in methanol. The remaining steps of 
the staining procedure, including blocking, secondary 
antibody incubation, and ABC reagent addition, were 
performed using the VECTASTAIN Elite ABC Kit 
(Vector Laboratories, Burlingame, CA) according to the 
manufacturer’s protocol. Primary antibodies were diluted 
in TBS/0.1% Tween-20 with 5% normal goat serum and 
were incubated at 4°C overnight. Color development 
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was performed using DAB Tablets (Wako Chemicals, 
Richmond, VA) as a substrate per manufacturer’s 
instruction. Finally, the sections were counterstained by 
hematoxylin, dehydrated in an ascending ethanol gradient, 
and mounted with VECTSHIELD Mounting Medium 
(Vector Laboratories, Burlingame, CA).
Semi-quantitative measurement of ASPH 
expression levels
IHC stained slides of PC tissue microarrays were 
observed at 400× magnification and the staining results 
were scored. Tumor cells were evaluated for ASPH 
expression with comparison to surrounding normal 
pancreas, acute/chronic pancreatitis, normal intestine, and 
pancreatic neuroendocrine tumors. 
ASPH mutant and shRNA constructs
We inhibited ASPH function by generating a 
mutant H675Q construct, which reduces β-hydroxylase 
activity to 20% of “wild type” (WT) level, or by shRNAs 
“knockdown”. The structures of WT-ASPH and H675Q 
mutant expression constructs that were inserted into the 
pCDNA3 vectors are shown in Fig. 4. Inclusion of a c-Myc 
tag allowed for discrimination between exogenous and 
endogenous protein levels. Empty vector, WT-ASPH and 
H675Q-ASPH overexpressing stable MIA PaCa2 PC cell 
lines were established by using the lentiviral expression 
system (GeneCopoeia). The ASPH H675Q mutant, which 
substantially reduced the β-hydroxylase activity, was 
compared to the WT-ASPH with respect to effects on cell 
proliferation, migration, invasion, and colony formation of 
stable MIA PaCa2 cells. These constructs were also tested 
for inhibition of Notch signaling as a downstream effector 
of ASPH biological activity. The ASPH protein level 
was confirmed by Western blot and immunofluorescent 
staining. The ASPH overexpressing MIA PaCa2 stable PC 
cell line is shown in Fig. 1f. Notch signaling components 
were assessed by measuring expression profiling of ASPH-
Notch network genes through Western blot analysis. 
Expression levels of activated Notch1 and HES1 were 
evaluated by immunohistochemistry staining in tissue 
samples derived from PC patients as shown in Fig. 1d.
High throughput screening assay for 
β-hydroxylase activity inhibition
The information on the strategy, methods and 
development of an assay to measure ASPH enzymatic 
activity is as described [11, 12]. 
Statistical analysis
All results were expressed as mean ± SD. Statistical 
analyses were performed with the two-tailed Student’s 
t-test or Wilcoxon rank sum test between control and 
treatment groups using SPSS software. Due to the normal 
distribution of the results, comparisons between PC 
tumor and adjacent non-neoplastic tissue were evaluated 
by paired t-tests. A p value of <0.05 was considered 
statistically significant.
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